The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
Kuifeng He1, Binbin Cui2, Guangliang Li1, Haohao Wang1, Ketao Jin1, Lisong Teng11Department of Surgical Oncology, First Affiliated Hospital, 2Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaAbstract: Significant progressi...
Main Authors: | He K, Cui B, Li G, Wang H, Jin K, Teng L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-04-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/the-effect-of-anti-vegf-drugs-bevacizumab-and-aflibercept-on-the-survi-a9689 |
Similar Items
-
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
by: Saif MW
Published: (2013-06-01) -
Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
by: Wafik S. El-Deiry, et al.
Published: (2019-03-01) -
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
by: Rossi L, et al.
Published: (2013-11-01) -
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
by: Ian Chau, et al.
Published: (2020-03-01) -
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
by: Ankur Bahl, et al.
Published: (2020-06-01)